Medical devices, healthcare technology and the business of care
510(k) clearance · K261749

Cardinal Health Nitrile Blue Examination Gloves Tested for Use with Chemotherapy Drugs and Fentanyl Citrate

Cardinalhealth · Decision date Sep 2, 2026

MEDTECHLEDGER EXPLANATIONK261749

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 09/02/2026 for K261749, a traditional 510(k) submitted by Cardinalhealth of Waukegan, Illinois, and received 05/28/2026. The device is listed as Cardinal Health Nitrile Blue Examination Gloves Tested for Use with Chemotherapy Drugs and Fentanyl Citrate, under device classification name Polymer Patient Examination Glove, regulation number 880.6250, with primary product code LZA and subsequent codes LZC, OPJ and QDO. The review panel and regulation medical specialty are both General Hospital. SESE denotes clearance of the submission, not premarket approval.

The record shows the submission was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The public page does not include the summary statement content, so the specific glove components, test methods, comparator devices and the basis for the chemotherapy-drug and fentanyl citrate testing claims remain unknown from this source. No clinical, efficacy or legal conclusion about the gloves is drawn here.

The page carries two differing last-updated dates, 10/26/2026 and 09/21/2026, and the source does not reconcile them.

Regulatory pathway
510(k) premarket notification
Clinical specialty
General Hospital
Decision date
Sep 2, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261749
Regulatory pathway
510(k) premarket notification
Product code
LZA
Decision code
SESE
Decision date
Sep 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Polymer Patient Examination Glove.

Product code
LZA
FDA device class
1

FDA decision timeline

  1. K261749 received

    Application receipt date recorded by FDA.

  2. K261749 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LZA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cardinalhealth

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Waukegan, IL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records